Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
An Open-Label Randomized Control Trial Comparing Clonidine and Buprenorphine for Medically-Assisted Opium Withdrawal of Adolescents Publisher



Firouzkouhi Moghadam M1 ; Bakhshani NM2, 3 ; Noroozi A4 ; Mood FS5 ; Lotfinia S6
Authors
Show Affiliations
Authors Affiliations
  1. 1. Children and Adolescent Health Research Center, Department of Psychiatry, Zahedan University of Medical Sciences, Zahedan, IR, Iran
  2. 2. Children and Adolescent Health Research Center, Department of Clinical Psychology, Zahedan University of Medical Sciences, Zahedan, IR, Iran
  3. 3. Infectious Disease and Tropical Medicine Research Center, Zahedan University of Medical Sciences, Zahedan, IR, Iran
  4. 4. Iranian National Center for Addiction Studies, Tehran University of Medical Sciences, Tehran, IR, Iran
  5. 5. Department of Psychiatric, Zahedan University of Medical Science, Zahedan, IR, Iran
  6. 6. Department of Clinical psychology, Zahedan University of Medical Science, Zahedan, IR, Iran

Source: International Journal of High Risk Behaviors and Addiction Published:2020


Abstract

Background: There is an increasing trend in treatment demand for opioid dependence among adolescents in Iran. However, evidence regarding effective treatment in this population is very limited. Objectives: This study aimed to compare the efficacy of clonidine and buprenorphine for inpatient medically-assisted withdrawal of adolescents with opioid dependence aged 12 and 16 years. Materials and Methods: The study is an open-label, randomized controlled trial with convenience sampling. In total, 36 adolescents took part in this study who were randomly assigned to buprenorphine or clonidine groups. The Clinical Opiate Withdrawal Scale was used to monitor the withdrawal severity on days one, two, three, seven, and 14. Results: The findings showed both treatments were effective. However, withdrawal symptoms in the buprenorphine group showed a greater reduction in the first seven days of withdrawal treatment. There was no significant difference in the length of hospitalization between the two groups. Patients with a longer duration of opioid use showed higher levels of withdrawal symptoms in the buprenorphine group on days one and three. Conclusions: Buprenorphine treatment was found to be more effective than clonidine in controlling opioid withdrawal during the initial days of treatment. However, it lost its superiority towards the end of the follow-up. It seems that clonidine could be a good alternative to buprenorphine in the medically-assisted withdrawal of adolescents with opioid dependence. Copyright © 2020, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
Experts (# of related papers)